SightfileU.S. market data from official filings

CRESCENT BIOPHARMA INC. (CBIO)

Name: CRESCENT BIOPHARMA INC. (CBIO) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001253689 · EDGAR filings · Updated 2026-07-20

CRESCENT BIOPHARMA INC. (CBIO) has reported institutional ownership of 91.1%, with 60 institutional managers holding positions valued at $461.3M per the latest 13F reporting period.

Institutional ownership

91.1%

Institutional managers

Reported 13F value

$461.3M

Insider activity

20 trans.

$18.2M net buying

Latest updates

2026-07-20 — SCHEDULE 13D/A filed
2026-07-20 — Insider transaction reported (Form 4)
2026-07-15 — Current report (8-K) filed
2026-07-15 — Prospectus supplement (424B5) filed
2026-07-14 — Current report (8-K) filed
2026-07-14 — Prospectus supplement (424B5) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, CRESCENT BIOPHARMA INC. has 60 institutional holders and institutional ownership of 91.1%.

Insider activity

Insiders reported 20 transactions (1 buys, 0 sells) across 11 reporting insiders, with a net reported value of $18.2M.

Related companies

4D MOLECULAR THERAPEUTICS IN (FDMT) · BIOVENTUS (BVS) · AVALO THERAPEUTICS INC (AVTX) · LEXEO THERAPEUTICS INC (LXEO) · INMODE LTD (INMD) · MIMEDX GROUP INC (MDXG)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-20.